Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3

Blood

Volumn 114, Issue 2, 2009, Pages 394-403

  Fukuda, Seiji ^a,b   Singh, Pratibha ^a   Moh, Akira ^a   Abe, Mariko ^b   Conway, Edward M ^c   Scott Boswell, H ^a   Yamaguchi, Seiji ^b   Fu, Xin Yuan ^a   Pelus, Louis M ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIMETHOXY 2 PHENYLQUINOXALINE; ATAXIN 1; CASPASE 3; CD135 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SEMAXANIB; STEM CELL FACTOR; SURVIVIN; FLT3 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; SURVIVIN PROTEIN, MOUSE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; COLONY FORMATION; COLONY FORMING UNIT GM; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; ACUTE DISEASE; ANIMAL; CANCER TRANSPLANTATION; CYTOLOGY; DRUG ANTAGONISM; ENZYME ACTIVATION; GENETICS; LEUKEMIA; METABOLISM; MUTATION; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL CULTURE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ACUTE DISEASE; ANIMALS; CASPASE 3; CELL PROLIFERATION; ENZYME ACTIVATION; FMS-LIKE TYROSINE KINASE 3; GENE DELETION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA; MICE; MICE, TRANSGENIC; MICROTUBULE-ASSOCIATED PROTEINS; MUTATION; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 67651108920     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-11-188714     Document Type: Article

References (51)

1. Lyman SD, James L, Vanden Bos T, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell. 1993;75:1157-1167. (Pubitemid 24006112)
2. Zhang S, Fukuda S, Lee Y, et al. Essential role of signal transducer and activator of transcription Stat5a but not Stat5b for Flt3-dependent signaling. J Exp Med. 2000;192:719-728. (Pubitemid 30688800)
3. Takahira H, Lyman SD, Broxmeyer HE. Flt3 ligand prolongs survival of CD34+++ human umbilical cord blood myeloid progenitors in serumdepleted culture medium. Ann Hematol. 1996;72: 131-135. (Pubitemid 26107623)
4. Shibayama H, Anzai N, Ritchie A, et al. Interleukin- 3 and Flt3-ligand induce adhesion of BaF3/ Flt3 precursor B-lymphoid cells to fibronectin via activation of VLA-4 and VLA-5. Cell Immunol. 1998;187:27-33. (Pubitemid 28359691)
5. Fukuda S, Broxmeyer HE, Pelus LM. Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1α(CXCL12)/ CXCR4 axis. Blood. 2005;105:3117-3126. (Pubitemid 40504329)
6. Fukuda S, Pelus LM. Internal tandem duplication of Flt3 (ITD-Flt3) modulates chemotaxis and survival of hematopoietic cells by SDF1α but negatively regulates marrow homing in vivo. Exp Hematol. 2006;34:1041-1051. (Pubitemid 44080382)
7. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100: 1532-1542.
8. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911-1918. (Pubitemid 27019637)
9. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001; 97:3589-3595.
10. Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97:89-94. (Pubitemid 32061246)
11. Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000;96: 3907-3914.
12. Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002;99: 3885-3891. (Pubitemid 35332023)
13. Hayakawa F, Towatari M, Kiyoi H, et al. Tandemduplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19:624-631. (Pubitemid 30102913)
14. Zheng R, Friedman AD, Levis M, et al. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. Blood. 2004;103:1883-1890. (Pubitemid 38268987)
15. Chen P, Levis M, Brown P, et al. FLT3/ITD mutation signaling includes suppression of SHP-1. J Biol Chem. 2005;280:5361-5369. (Pubitemid 40280010)
16. Tse KF, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia. 2000;14:1766-1776. (Pubitemid 30756774)
17. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004; 103:3669-3676. (Pubitemid 38596280)
18. Fiedler W, Mesters R, Tinnefeld H, et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood. 2003;102: 2763-2767. (Pubitemid 37248845)
19. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3:650-665.
20. Li F, Ackermann EJ, Bennett CF, et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol. 1999;1:461-466. (Pubitemid 129503664)
21. Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921. (Pubitemid 27353455)
22. Kobayashi K, Hatano M, Otaki M, Ogasawara T, Tokuhisa T. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc Natl Acad Sci U S A. 1999;96: 1457-1462. (Pubitemid 29098472)
23. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580-584. (Pubitemid 28563719)
24. Carter BZ, Miella M, Altieri DC, Andreeff M. Cytokineregulated expression of survivin in myeloid leukemia. Blood. 2001;97:2784-2790.
25. Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol. 2000; 111:196-203. (Pubitemid 30832451)
26. Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes. Nat Genet. 1999; 23:387-388.
27. Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 2001;40:1117-1123. (Pubitemid 32108606)
28. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58: 5315-5320. (Pubitemid 28551107)
29. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006;5:1087-1098. (Pubitemid 43881300)
30. Wang Z, Sampath J, Fukuda S, Pelus LM. Disruption of the inhibitor of apoptosis protein, survivin, sensitizes Bcr-abl positive cells to STI571- induced apoptosis. Cancer Res. 2005;65:8224-8232. (Pubitemid 41330586)
31. Fukuda S, Pelus LM. Activated H-Ras regulates hematopoietic cell survival by modulating Survivin. Biochem Biophys Res Commun. 2004;323: 636-644. (Pubitemid 39221143)
32. Zheng R, Levis R, Piloto O, et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood. 2004;103:267-274. (Pubitemid 38029948)
33. Fukuda S, Pelus LM. Regulation of the inhibitorof- apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood. 2001;98:2091-2100. (Pubitemid 33785791)
34. Kelly LM, Liu Q, Kutok JL, et al. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood. 2002;99:310-318.
35. Fukuda S, Mantel CR, Pelus LM. Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1 dependent and independent pathways. Blood. 2004;103:120-127. (Pubitemid 38029926)
36. Fukuda S, Foster RG, Porter SB, Pelus LM. The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood. 2002;100:2463-2471.
37. Xing Z, Conway EM, Kang C, Winoto A. Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med. 2004;199:69-80. (Pubitemid 38076479)
38. Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/ inactivation in the mouse. Dev Biol. 2002; 244:305-318. (Pubitemid 34450645)
39. Yee KW, O'Farrell AM, Smolich BD, et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood. 2002;100:2941-2949.
40. Lee BH, Tothova Z, Levine RL, et al. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell. 2007;12:367-380. (Pubitemid 47554548)
41. Fukuda S, Conway EM, Pelus LM. Survivin regulates proliferation of normal hematopoietic stem and progenitor cells in vivo [abstract]. Blood (ASH Annual Meeting Abstracts). 2006;108:859.
42. Li L, Piloto O, Nguyen HB, et al. Knock-in of aninternal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. Blood. 2008;111:3849-3858.
43. Lee BH, Williams IR, Anastasiadou E, et al. FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. Oncogene. 2005;24:7882-7892. (Pubitemid 41715194)
44. Stong RC, Korsmeyer SJ, Parkin JL, Arthur DC, Kersey JH. Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood. 1985;65:21-31.
45. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 2003;101:1535-1542. (Pubitemid 36182531)
46. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA. Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem. 2004; 279:40511-40520. (Pubitemid 39287642)
47. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002;277:3247-3257. (Pubitemid 34953189)
48. Tracey L, Perez-Rosado A, Artiga MJ, et al. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol. 2005;206:123-134. (Pubitemid 40754015)
49. Laouar Y, Welte T, Fu XY, Flavell RA. STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity. 2003;19:903-912. (Pubitemid 37542309)
50. Kelly LM, Kutok JL, Williams IR, et al. PML/ RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci U S A. 2002;99:8283-8288.
51. Levis M, Murphy KM, Pham R, et al. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood. 2005; 106:673-680. (Pubitemid 40981265)